BFM
RCUS icon

Boothbay Fund Management’s Arcus Biosciences RCUS Stock Holding History

Boothbay Fund Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-175,700
Closed -$3.15M – 1922
2023
Q3 		$3.15M Sell
175,700
-100,000
-36% -$2.01M 0.07% 356
2023
Q2 		$5.6M Buy
275,700
+104,400
+61% +$1.99M 0.12% 186
2023
Q1 		$3.12M Buy
171,300
+114,900
+204% +$2.2M 0.06% 466
2022
Q4 		$1.17M Buy
+56,400
New +$1.55M 0.03% 830
2022
Q2 		– Sell
-123,200
Closed -$3.89M – 2599
2022
Q1 		$3.89M Buy
123,200
+92,600
+303% +$3.1M 0.09% 292
2021
Q4 		$1.24M Buy
+30,600
New +$1.19M 0.03% 663
2021
Q3 		– Sell
-28,700
Closed -$788K – 2135
2021
Q2 		$788K Buy
28,700
+28,413
+9,900% +$812K 0.03% 801
2021
Q1 		$806K Buy
+287
New +$9.99K 0.03% 708

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's RCUS Position: Q3 2025 in Review

Boothbay Fund Management sold out of Arcus Biosciences (RCUS) in Q3 2025, closing a stake of 99,457 shares — an estimated $810K sold.

Boothbay Fund Management first reported a position in RCUS in Q1 2022 and held it in 10 quarters. The position peaked at $3.98M in Q1 2023. 190 funds tracked by Wall St. Rank hold RCUS as of Q3 2025.

  • Boothbay Fund Management reported no remaining Arcus Biosciences position as of Q3 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 99,457 Arcus Biosciences shares in Q3 2025, an estimated $810K.
  • Boothbay Fund Management first reported a position in Arcus Biosciences in Q1 2022 and held it in 10 quarters.
  • Boothbay Fund Management's Arcus Biosciences position peaked at $3.98M in Q1 2023.
  • 190 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2025.

Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.